Literature DB >> 24409049

Liver transplantation for hilar cholangiocarcinoma.

Ricardo Robles1, Francisco Sánchez-Bueno1, Pablo Ramírez1, Roberto Brusadin1, Pascual Parrilla1.   

Abstract

The most appropriate treatment for Klatskin tumor (KT) with a curative intention is multimodal therapy based on achieving resection with tumour-free margins (R0 resections) combined with other types of neoadjuvant or adjuvant treatment (the most important factor affecting KT survival is the possibility of R0 resections, achieving 5-year survival rate of 40%-50%). Thirty to forty percent of patients with KT are inoperable and present a 5-year survival rate of 0%. In irresectable non-disseminated KT patients, using liver transplantation without neoadjuvant treatment, the 5-year survival rate increase to 38%, reaching 50% survival in early stage. In selected cases, with liver transplantation and neoadjuvant treatment (chemotherapy and radiotherapy), the actuarial survival rate is 65% at 5 years and 59% at 10 years. In conclusion, correct staging, neoadjuvant treatment, living donor and priority on the liver transplant waiting list may lead to improved results.

Entities:  

Keywords:  Cholangiocarcinoma; Klatskin tumour; Liver surgery; Liver transplantation; Primary sclerosing cholangitis

Mesh:

Year:  2013        PMID: 24409049      PMCID: PMC3882395          DOI: 10.3748/wjg.v19.i48.9209

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  62 in total

1.  Can we cure cholangiocarcinoma with neoadjuvant chemoradiation and liver transplantation? Time for a multicenter trial.

Authors:  Robin K Kelley; Ryutaro Hirose; Alan P Venook
Journal:  Liver Transpl       Date:  2012-05       Impact factor: 5.799

Review 2.  Liver transplantation for cholangiocarcinoma.

Authors:  Charles B Rosen; Julie K Heimbach; Gregory J Gores
Journal:  Transpl Int       Date:  2010-05-20       Impact factor: 3.782

Review 3.  Liver transplantation for cholangiocellular carcinoma: analysis of a single-center experience and review of the literature.

Authors:  M Shimoda; D G Farmer; S D Colquhoun; M Rosove; R M Ghobrial; H Yersiz; P Chen; R W Busuttil
Journal:  Liver Transpl       Date:  2001-12       Impact factor: 5.799

Review 4.  Is liver transplantation indicated for cholangiocarcinoma?

Authors:  D R Jeyarajah; G B Klintmalm
Journal:  J Hepatobiliary Pancreat Surg       Date:  1998

5.  Abdominal organ cluster transplantation for the treatment of upper abdominal malignancies.

Authors:  T E Starzl; S Todo; A Tzakis; L Podesta; L Mieles; A Demetris; L Teperman; R Selby; W Stevenson; A Stieber
Journal:  Ann Surg       Date:  1989-09       Impact factor: 12.969

6.  Predictors of pretransplant dropout and posttransplant recurrence in patients with perihilar cholangiocarcinoma.

Authors:  Sarwa Darwish Murad; W Ray Kim; Terry Therneau; Gregory J Gores; Charles B Rosen; James A Martenson; Steven R Alberts; Julie K Heimbach
Journal:  Hepatology       Date:  2012-07-17       Impact factor: 17.425

7.  Long-term survival after intraluminal brachytherapy for inoperable hilar cholangiocarcinoma: a case report.

Authors:  Siu-Yin Chan; Ronnie T Poon; Kelvin K Ng; Chi-Leung Liu; Raymond T Chan; Sheung-Tat Fan
Journal:  World J Gastroenterol       Date:  2005-05-28       Impact factor: 5.742

Review 8.  Liver transplantation and pancreatic resection: a single-center experience and a review of the literature.

Authors:  John A Stauffer; Jeffery L Steers; Hugo Bonatti; Marjorie K Dougherty; Jaime Aranda-Michel; Rolland C Dickson; Denise M Harnois; Justin H Nguyen
Journal:  Liver Transpl       Date:  2009-12       Impact factor: 5.799

Review 9.  A review and update on cholangiocarcinoma.

Authors:  Matthew J Olnes; Rodrigo Erlich
Journal:  Oncology       Date:  2004       Impact factor: 2.935

10.  Right or left trisegment portal vein embolization before hepatic trisegmentectomy for hilar bile duct carcinoma.

Authors:  M Nagino; Y Nimura; J Kamiya; S Kondo; K Uesaka; Y Kin; Y Kutsuna; N Hayakawa; H Yamamoto
Journal:  Surgery       Date:  1995-06       Impact factor: 3.982

View more
  10 in total

1.  Recurrent Cholangiocarcinoma Presenting as Sister Mary Joseph Nodule After Liver Transplantation.

Authors:  Vijayadershan Muppidi; Sreenath Meegada; James D Eason; Satheesh P Nair; Rajanshu Verma
Journal:  Cureus       Date:  2020-11-24

Review 2.  Association between Helicobacter spp. infections and hepatobiliary malignancies: a review.

Authors:  Fany Karina Segura-López; Alfredo Güitrón-Cantú; Javier Torres
Journal:  World J Gastroenterol       Date:  2015-02-07       Impact factor: 5.742

3.  Outcomes of liver transplantation for end-stage biliary disease: A comparative study with end-stage liver disease.

Authors:  Yan-Hua Lai; Wei-Dong Duan; Qiang Yu; Sheng Ye; Nian-Jun Xiao; Dong-Xin Zhang; Zhi-Qiang Huang; Zhan-Yu Yang; Jia-Hong Dong
Journal:  World J Gastroenterol       Date:  2015-05-28       Impact factor: 5.742

4.  Use of an autologous liver round ligament flap zeros postoperative bile leak after curative resection of hilar cholangiocarcinoma.

Authors:  Da-Xin Sun; Xiao-Dong Tan; Feng Gao; Jin Xu; Dong-Xu Cui; Xian-Wei Dai
Journal:  PLoS One       Date:  2015-05-04       Impact factor: 3.240

5.  Stereotactic Body Radiotherapy (SBRT) for Intrahepatic and Hilar Cholangiocarcinoma.

Authors:  Anand Mahadevan; Nergiz Dagoglu; Joseph Mancias; Kristin Raven; Khalid Khwaja; Jennifer F Tseng; Kimmie Ng; Peter Enzinger; Rebecca Miksad; Andrea Bullock; Amy Evenson
Journal:  J Cancer       Date:  2015-08-01       Impact factor: 4.207

6.  Elevated red blood cell distribution width predicts poor prognosis in hilar cholangiocarcinoma.

Authors:  Bei Li; Zhen You; Xian-Ze Xiong; Yong Zhou; Si-Jia Wu; Rong-Xing Zhou; Jiong Lu; Nan-Sheng Cheng
Journal:  Oncotarget       Date:  2017-11-25

7.  Controlling Nutritional Status (CONUT) Score as a New Indicator of Prognosis in Patients With Hilar Cholangiocarcinoma Is Superior to NLR and PNI: A Single-Center Retrospective Study.

Authors:  Ankang Wang; Zhenxing He; Peng Cong; Yueyu Qu; Tao Hu; Yu Cai; Bo Sun; Hao Chen; Wenguang Fu; Yong Peng
Journal:  Front Oncol       Date:  2021-01-11       Impact factor: 6.244

8.  Postoperative morbidity adversely impacts oncological prognosis after curative resection for hilar cholangiocarcinoma.

Authors:  Zhi-Peng Liu; Wei-Yue Chen; Yan-Qi Zhang; Yan Jiang; Jie Bai; Yu Pan; Shi-Yun Zhong; Yun-Ping Zhong; Zhi-Yu Chen; Hai-Su Dai
Journal:  World J Gastroenterol       Date:  2022-03-07       Impact factor: 5.742

9.  Detection of Primary Malignancy and Metastases with FDG PET/CT in Patients with Cholangiocarcinomas: Lesion-based Comparison with Contrast Enhanced CT.

Authors:  Youssef Elias; Aladin T Mariano; Yang Lu
Journal:  World J Nucl Med       Date:  2016-09

10.  Elevated platelet distribution width predicts poor prognosis in hilar cholangiocarcinoma.

Authors:  Bei Li; Jiong Lu; Ding-Zhong Peng; Xin-Yi Zhang; Zhen You
Journal:  Medicine (Baltimore)       Date:  2020-03       Impact factor: 1.817

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.